Harbour Investments’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Harbour Investments’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-183	Closed	-$128	–	3349
2023 Q4	$128	Hold	183	–	–	﹤0.01%	3035
2023 Q3	$126	Hold	183	–	–	﹤0.01%	2910
2023 Q2	$441	Sell	183 -1	-0.5%	-$4	﹤0.01%	2835
2023 Q1	$1.49K	Hold	184	–	–	﹤0.01%	2618
2022 Q4	$2.18K	Hold	184	–	–	﹤0.01%	2490
2022 Q3	$6K	Hold	184	–	–	﹤0.01%	2143
2022 Q2	$6K	Buy	+184	New	+$5.74K	﹤0.01%	2143
2021 Q4	–	Sell	-29	Closed	-$2K	–	3850
2021 Q3	$2K	Hold	29	–	–	﹤0.01%	3397
2021 Q2	$2K	Hold	29	–	–	﹤0.01%	3457
2021 Q1	$2K	Buy	+29	New	+$2.26K	﹤0.01%	3296

Other funds holding DMK

CPA

Clear Point Advisors Melville, New York $129M AUM 12.02% 1-Year Est. Return

OPTFSNA

Old Point Trust & Financial Services N A Newport News, Virginia $311M AUM 24.14% 1-Year Est. Return

Harbour Investments's DMK Position: Q1 2024 in Review

Harbour Investments sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2024, closing a stake of 183 shares — an estimated $128 sold.

Harbour Investments first reported a position in DMK in Q1 2021 and held it in 10 quarters. The position peaked at $6K in Q3 2022. 3 funds tracked by Wall St. Rank hold DMK as of Q1 2024.

Harbour Investments reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2024 after selling out during the quarter.
Harbour Investments sold 183 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2024, an estimated $128.
Harbour Investments first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q1 2021 and held it in 10 quarters.
Harbour Investments's DMK Pharmaceuticals Corporation Common Stock position peaked at $6K in Q3 2022.
3 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2024.

Based on Harbour Investments's 13F filing for Q1 2024, filed 22 Jul 2024.